Abstract：
OBJECTIVE: The aim of the current study was to evaluate the feasibility and effectiveness of CT-guided microwave ablation (MWA) in the treatment of osteoid osteomas (OO).
METHODS: Data from 59 consecutive patients who underwent percutaneous CT-MWA for OO treatment were examined in the current retrospective study. The period of this study spanned from January 2021 to May 2023 at a single institution. The study involved an evaluation of clinical and radiological characteristics, procedural data, Visual Analog Scale (VAS) pain scores, complication incidences, as well as clinical and technical success rates. Statistical analyses were performed by using the Wilcoxon test with Bonferroni correction, Friedman, Spearman, Mann-Whitney U test.
RESULTS: 59 patients with an average age of 17.31 ± 8.53 years underwent CT-guided MWA for the treatment of OO. The procedure demonstrated a high success rate, with 96.6% of cases achieving both technical and clinical success. However, recurrence was observed in two patients (3.4%) at the three-month follow-up. These cases were successfully managed with a second MWA procedure. The median VAS pain scores reported by the patients was significantly improved post-procedure: from 8.64 ± 1.14 before treatment to 0.63 ± 0.98 in the first month, 0.41 ± 1.02 in the third month, and 0.15 ± 0.45 in the sixth month. Only one patient (1.7%) experienced a minor complication; no major complications were recorded in this study.
CONCLUSIONS: CT-guided percutaneous MWA is a minimally invasive and a highly effective and safe approach for the treatment of OO.
METHODS: Data from 59 consecutive patients who underwent percutaneous CT-MWA for OO treatment were examined in the current retrospective study. The period of this study spanned from January 2021 to May 2023 at a single institution. The study involved an evaluation of clinical and radiological characteristics, procedural data, Visual Analog Scale (VAS) pain scores, complication incidences, as well as clinical and technical success rates. Statistical analyses were performed by using the Wilcoxon test with Bonferroni correction, Friedman, Spearman, Mann-Whitney U test.
RESULTS: 59 patients with an average age of 17.31 ± 8.53 years underwent CT-guided MWA for the treatment of OO. The procedure demonstrated a high success rate, with 96.6% of cases achieving both technical and clinical success. However, recurrence was observed in two patients (3.4%) at the three-month follow-up. These cases were successfully managed with a second MWA procedure. The median VAS pain scores reported by the patients was significantly improved post-procedure: from 8.64 ± 1.14 before treatment to 0.63 ± 0.98 in the first month, 0.41 ± 1.02 in the third month, and 0.15 ± 0.45 in the sixth month. Only one patient (1.7%) experienced a minor complication; no major complications were recorded in this study.
CONCLUSIONS: CT-guided percutaneous MWA is a minimally invasive and a highly effective and safe approach for the treatment of OO.
摘要：
目的：本研究的目的是评估CT引导下微波消融（MWA）治疗骨样骨瘤（OO）的可行性和有效性。
方法：在当前的回顾性研究中检查了59例接受经皮CT-MWA治疗的OO患者的数据。这项研究的时间从2021年1月到2023年5月在一个机构进行。该研究涉及临床和放射学特征的评估，程序数据,视觉模拟量表（VAS）疼痛评分，并发症发生率,以及临床和技术成功率。使用Wilcoxon检验和Bonferroni校正进行统计分析，弗里德曼,斯皮尔曼,曼-惠特尼U测试。
结果：59例平均年龄17.31±8.53岁的患者接受了CT引导的MWA治疗OO。该程序显示出很高的成功率，96.6%的病例在技术和临床上都取得了成功。然而,随访3个月时,2例患者(3.4%)出现复发.这些病例通过第二个MWA程序成功管理。患者报告的中位VAS疼痛评分在术后显着改善：从治疗前的8.64±1.14提高到第一个月的0.63±0.98。第三个月0.41±1.02，第六个月为0.15±0.45。只有一名患者（1.7％）经历了轻微的并发症；在这项研究中没有记录到主要的并发症。
结论：CT引导经皮MWA是治疗OO的一种微创、高效、安全的方法。
方法：在当前的回顾性研究中检查了59例接受经皮CT-MWA治疗的OO患者的数据。这项研究的时间从2021年1月到2023年5月在一个机构进行。该研究涉及临床和放射学特征的评估，程序数据,视觉模拟量表（VAS）疼痛评分，并发症发生率,以及临床和技术成功率。使用Wilcoxon检验和Bonferroni校正进行统计分析，弗里德曼,斯皮尔曼,曼-惠特尼U测试。
结果：59例平均年龄17.31±8.53岁的患者接受了CT引导的MWA治疗OO。该程序显示出很高的成功率，96.6%的病例在技术和临床上都取得了成功。然而,随访3个月时,2例患者(3.4%)出现复发.这些病例通过第二个MWA程序成功管理。患者报告的中位VAS疼痛评分在术后显着改善：从治疗前的8.64±1.14提高到第一个月的0.63±0.98。第三个月0.41±1.02，第六个月为0.15±0.45。只有一名患者（1.7％）经历了轻微的并发症；在这项研究中没有记录到主要的并发症。
结论：CT引导经皮MWA是治疗OO的一种微创、高效、安全的方法。
